ClinicalTrials.gg
RecruitingNCT07030959Updated Sep 29, 2026

Study of AUBE00 in Patients With Solid Tumors

A Phase 1 interventional study of AUBE00 and Cetuximab in Solid Tumors, sponsored by Chugai Pharmaceutical. Recruiting at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Chugai Pharmaceutical (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Sep 29, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
130
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human, Phase I, open-label, multicenter, multinational study, designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and anti-tumor activity of AUBE00 in patients with locally advanced or metastatic solid tumors.The total number of patients in this study will be approximately 90 to 130.

02

Conditions studied

  • Solid Tumors
03

In context

Lead sponsor

Chugai Pharmaceutical is the lead sponsor of 63 studies on the registry; 7 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

First submitted after Chugai Pharmaceutical became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at time of signing Form (ICF)
  • (ECOG) performance status of 0 or 1
  • Patients with Kirsten rat sarcoma (KRAS) alteration confirmed by local tests or central laboratory test (Details are defined for each part)
  • or resistant to standard therapies or standard therapies are not available

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intending to become pregnant or breastfeeding during the study or within 27 weeks after the last dose of AUBE00 or within 2 months after the last dose of cetuximab, whichever is longer.
  • Primary central nervous system (CNS) , untreated requiring any anti-tumor treatment, or active CNS metastases (progressing or requiring for symptomatic control)
  • Significant cardiovascular disease, such as (NYHA) Class II or greater cardiac disease, unstable angina, or myocardial infraction within the previous 6 months or unstable arrhythmias within the previous 3 months
  • Patient with complications from a cerebrovascular disorder (such as subarachnoid hemorrhage, cerebral infarction, , etc.) or a history of such complications within 6 months prior to enrollment
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Part A: Dose Escalation part of AUBE00 monotherapy with or without prophylactic management

    Patients will receive AUBE00 as an oral administration at escalated doses. Patients may also receive prophylactic management for treatment-related adverse events.

    Drug: AUBE00

  • Experimental
    Part B: Expansion part of AUBE00 monotherapy

    Patients will receive AUBE00 as an oral administration at multiple dose levels determined to be safe (including MTD).

    Drug: AUBE00

  • Experimental
    Part C: Dose-Escalation and Expansion part of AUBE00 in combination with Cetuximab

    Patients will receive AUBE00 as an oral administration in combination with cetuximab as an IV infusion at escalated doses or the recommended dose level.

    Drug: AUBE00 · Drug: Cetuximab

Interventions

  • DrugAUBE00

    AUBE00 as an oral administration

  • Cetuximab as an IV infusion

06

What researchers measure

Primary outcomes

  1. Adverse events of AUBE00 [Part A, B, C]

    Incidence, nature, and severity of adverse events (AEs), with severity determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0)

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  2. Number of participants with changes in vital signs of AUBE00 [Part A, B, C]

    Change from baseline in vital signs (Includes respiratory rate, pulse oximetry, pulse rate, and systolic and diastolic blood pressure while the patient is in a seated or semi-recumbent position, and temperature.)

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  3. Number of participants with changes in clinical laboratory test of AUBE00 [Part A, B, C]

    Change from baseline in clinical laboratory test

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  4. Number of participants with changes in Electrocardiograms (ECGs) of AUBE00 [Part A, B, C]

    Change from baseline in ECGs (QT interval)

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  5. Maximum tolerated dose (MTD) of AUBE00 [Part A, C]

    Incidence and nature of dose-limiting toxicities (DLTs)

    Time frame: From Cycle 0 Day 1 until Cycle 2 Day 1 (approximately 30 days) (Cycle 0: 6 to 9 days, Cycle 1 and beyond each Cycle: 21 days) [Part A]; From Cycle 1 Day 1 until Cycle 2 Day 1 (approximately 28 days) (Cycle 1 and beyond each Cycle: 28 days) [Part C]

  6. Time to reach maximum plasma concentration (Tmax) of AUBE00 [Part A]

    Tmax of AUBE00

    Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)

  7. Maximum plasma concentration (Cmax) of AUBE00 [Part A]

    Cmax of AUBE00

    Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)

  8. Elimination half-life (t1/2) of AUBE00 [Part A]

    t1/2 of AUBE00

    Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)

  9. Area under the plasma concentration-time curve (AUC) of AUBE00 [Part A]

    AUC of AUBE00

    Time frame: From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)

  10. Objective response of AUBE00 [Part B, C]

    Objective response, defined as a confirmed complete response (CR) or partial response (PR) as the best overall response per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as determined by the Investigator

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

Secondary outcomes

  1. Objective response of AUBE00 [Part A]

    Objective response, defined as a confirmed CR or PR as the best overall response per RECIST v1.1 as determined by the Investigator

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  2. Disease control of AUBE00 [Part A, B, C]

    Disease control, defined as a confirmed CR, PR, or stable disease (SD) per RECIST v1.1 as determined by the Investigator

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  3. Duration of response (DoR) of AUBE00 [Part A, B, C]

    DoR, defined as the time from the first occurrence of a documented objective response to the time of the first documented disease progression per RECIST v1.1 as determined by the Investigator or death due to any cause, whichever occurs first

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  4. Progression free survival (PFS) of AUBE00 [Part A, B, C]

    PFS, defined as the time from the first study treatment to the first occurrence of disease progression per RECIST v1.1 as determined by the Investigator or death due to any cause, whichever occurs first

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  5. Anti-AUBE00 antibodies of AUBE00 [Part A, B, C]

    Incidence of anti-AUBE00 antibodies

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  6. Overall survival (OS) of AUBE00 [Part B, C]

    OS, defined as the time from the date of first study treatment to death due to any cause

    Time frame: From screening until study completion, treatment discontinuation or post-treatment follow up (up to approximately 55 months)

  7. Time to reach maximum plasma concentration (Tmax) of AUBE00 [Part B, C]

    Tmax of AUBE00

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  8. Maximum plasma concentration (Cmax) of AUBE00 [Part B, C]

    Cmax of AUBE00

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  9. Elimination half-life (t1/2) of AUBE00 [Part B, C]

    t1/2 of AUBE00

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)[Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  10. Area under the plasma concentration-time curve (AUC) of AUBE00 [Part B, C]

    AUC of AUBE00

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months)[Part B]. From Cycle 0 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  11. Time to reach maximum serum concentration (Tmax) of cetuximab [Part C]

    Tmax of cetuximab

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  12. Maximum serum concentration (Cmax) of cetuximab [Part C]

    Cmax of cetuximab

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  13. Elimination half-life (t1/2) of cetuximab [Part C]

    t1/2 of cetuximab

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  14. Area under the serum concentration-time curve (AUC) of cetuximab [Part C]

    AUC of cetuximab

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

  15. Anti-cetuximab antibodies of cetuximab [Part C]

    Incidence of anti-cetuximab antibodies

    Time frame: From Cycle 1 Day 1 until study completion, treatment discontinuation (up to approximately 55 months) [Part C].

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform. For further details on Chugai's Data Sharing Policy and how to request access to related clinical study documents, see here (www.chugai-pharm.co.jp/english/profile/rd/ctds_request.html).

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Dec 2029, 54 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2025
First posted
Jun 22, 2025
StartActual
Jun 5, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • NEXT Oncology Virginia · Fairfax, United States
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    1 site added
    Show site
    • NEXT Oncology Virginia · Fairfax, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07030959
Responsible party
Sponsor
First posted
Jun 22, 2025
Start date
Jun 5, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Clinical trials information
Contact
clinical-trials@chugai-pharm.co.jp
only use Email
Sponsor Chugai Pharmaceutical Co.Ltd
study director · clinical-trials@chugai-pharm.co.jp

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion